Loading...
Loading...
AADI| Name | Value |
|---|---|
| Revenues | 7.2M |
| Cost of Revenue | 0.8M |
| Gross Profit | 6.4M |
| Operating Expense | 19.8M |
| Operating I/L | -13.4M |
| Other Income/Expense | 0.9M |
| Interest Income | 0.9M |
| Pretax | -12.5M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -12.5M |
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company specializing in precision therapies for genetically defined cancers with mTOR pathway gene alterations. Their lead drug candidate, FYARRO, is a form of sirolimus bound to albumin, being evaluated in cancers with known mTOR pathway activation. Aadi is focused on developing and commercializing therapies for tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway, aiming to generate revenue through the successful development and commercialization of these precision therapies.
